BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:R289 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of R289\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05308264-10823@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:R289: Phase 1/2 readout est. (NCT05308264)
DESCRIPTION:R289\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: Study of 
 R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/r289#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05308264
URL:https://assetmemo.bio/drug/r289#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
